Connect Biopharma Reports Third Quarter 2026 Financial Results and Provides Business Update
– Reported positive preliminary topline data from global Phase 2 Seabreeze STAT studies evaluating rademikibart as an adjunct treatment for acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD) –